New Insights in Melanoma Biomarkers: Long-noncoding RNAs

Overview

Journal Melanoma Manag

Date 2018 Sep 8

PMID 30190889

Citations 1

Authors

Ricardo Moreno-Traspas

Igor Vujic

Martina Sanlorenzo

Susana Ortiz-Urda

Affiliations

Soon will be listed here.

Abstract

Melanoma is one of the leading cancers worldwide, distinguished for its malignancy and low survival rates. Although the poor outcome could improve with an early diagnosis and a good monitoring of the disease, current melanoma biomarkers display several limitations which make them useless. Interestingly, long-noncoding RNAs are secreted into the bloodstream inside exosomes by a wide range of malignant cells, and several of them have been validated as promising circulating molecular signatures of other tumors, but not melanoma. In this review we propose to explore the booming field of long-noncoding RNAs in order to find potential candidates to be tested as novel melanoma biomarkers, with the ultimate goal of improving melanoma detection, diagnosis and prognosis.

Citing Articles

Glycolysis regulated exosomal LINC01214 inhibited CD8 T cell function and induced anti-PD1 resistance in melanoma via modulating miR-4492/PPP1R11 axis.

Ding Z, Wu B, Yang J, Wang D, Qiao J, Guo F Noncoding RNA Res. 2024; 10:242-251.

PMID: 39559293 PMC: 11570817. DOI: 10.1016/j.ncrna.2024.10.005.

References

Marcoval J, Ferreres J, Martin C, Gomez S, Penin R, Ochoa de Olza M . Patterns of visceral metastasis in cutaneous melanoma: a descriptive study. Actas Dermosifiliogr. 2013; 104(7):593-7. DOI: 10.1016/j.adengl.2012.12.006. View

Wellbrock C . MAPK pathway inhibition in melanoma: resistance three ways. Biochem Soc Trans. 2014; 42(4):727-32. DOI: 10.1042/BST20140020. View

Wolchok J, Kluger H, Callahan M, Postow M, Rizvi N, Lesokhin A . Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2013; 369(2):122-33. PMC: 5698004. DOI: 10.1056/NEJMoa1302369. View

. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001; 69(3):89-95. DOI: 10.1067/mcp.2001.113989. View

Gray E, Rizos H, Reid A, Boyd S, Pereira M, Lo J . Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma. Oncotarget. 2015; 6(39):42008-18. PMC: 4747205. DOI: 10.18632/oncotarget.5788. View

Krahn G, Kaskel P, Sander S, Waizenhofer P, Wortmann S, Leiter U . S100 beta is a more reliable tumor marker in peripheral blood for patients with newly occurred melanoma metastases compared with MIA, albumin and lactate-dehydrogenase. Anticancer Res. 2001; 21(2B):1311-6. View

Garg R, McPherson T, Lentle B, Jackson F . Usefulness of an elevated serum lactate dehydrogenase value as a marker of hepatic metastases in malignant melanoma. Can Med Assoc J. 1979; 120(9):1114, 1116. PMC: 1819289. View

Tian Y, Zhang X, Hao Y, Fang Z, He Y . Potential roles of abnormally expressed long noncoding RNA UCA1 and Malat-1 in metastasis of melanoma. Melanoma Res. 2014; 24(4):335-41. DOI: 10.1097/CMR.0000000000000080. View

Ugurel S, Rappl G, Tilgen W, Reinhold U . Increased serum concentration of angiogenic factors in malignant melanoma patients correlates with tumor progression and survival. J Clin Oncol. 2001; 19(2):577-83. DOI: 10.1200/JCO.2001.19.2.577. View

10.

Deichmann M, Benner A, Bock M, Jackel A, Uhl K, Waldmann V . S100-Beta, melanoma-inhibiting activity, and lactate dehydrogenase discriminate progressive from nonprogressive American Joint Committee on Cancer stage IV melanoma. J Clin Oncol. 1999; 17(6):1891-6. DOI: 10.1200/JCO.1999.17.6.1891. View

11.

Kiyohara E, Hata K, Lam S, Hoon D . Circulating tumor cells as prognostic biomarkers in cutaneous melanoma patients. Methods Mol Biol. 2013; 1102:513-22. DOI: 10.1007/978-1-62703-727-3_27. View

12.

Takahashi K, Yan I, Kogure T, Haga H, Patel T . Extracellular vesicle-mediated transfer of long non-coding RNA ROR modulates chemosensitivity in human hepatocellular cancer. FEBS Open Bio. 2014; 4:458-67. PMC: 4050189. DOI: 10.1016/j.fob.2014.04.007. View

13.

Khaitan D, Dinger M, Mazar J, Crawford J, Smith M, Mattick J . The melanoma-upregulated long noncoding RNA SPRY4-IT1 modulates apoptosis and invasion. Cancer Res. 2011; 71(11):3852-62. DOI: 10.1158/0008-5472.CAN-10-4460. View

14.

Li Q, Shao Y, Zhang X, Zheng T, Miao M, Qin L . Plasma long noncoding RNA protected by exosomes as a potential stable biomarker for gastric cancer. Tumour Biol. 2014; 36(3):2007-12. DOI: 10.1007/s13277-014-2807-y. View

15.

Margue C, Reinsbach S, Philippidou D, Beaume N, Walters C, Schneider J . Comparison of a healthy miRNome with melanoma patient miRNomes: are microRNAs suitable serum biomarkers for cancer?. Oncotarget. 2015; 6(14):12110-27. PMC: 4494926. DOI: 10.18632/oncotarget.3661. View

16.

Little E, Eide M . Update on the current state of melanoma incidence. Dermatol Clin. 2012; 30(3):355-61. DOI: 10.1016/j.det.2012.04.001. View

17.

Postow M, Callahan M, Wolchok J . Immune Checkpoint Blockade in Cancer Therapy. J Clin Oncol. 2015; 33(17):1974-82. PMC: 4980573. DOI: 10.1200/JCO.2014.59.4358. View

18.

Tang L, Zhang W, Su B, Yu B . Long noncoding RNA HOTAIR is associated with motility, invasion, and metastatic potential of metastatic melanoma. Biomed Res Int. 2013; 2013:251098. PMC: 3687722. DOI: 10.1155/2013/251098. View

19.

Hatzimichael E, Syed N, Lo Nigro C, Rao B, Crook T . How detection of epigenetic alterations of blood-borne DNA could improve melanoma diagnosis. Expert Rev Mol Diagn. 2014; 14(6):639-42. DOI: 10.1586/14737159.2014.928204. View

20.

Bottoni U, Izzo P, Richetta A, Mannooranparampil T, Devirgiliis V, Del Giudice M . S100 serum level: a tumour marker for metastatic melanoma. Melanoma Res. 2003; 13(4):427-9. DOI: 10.1097/01.cmr.0000056253.56735.53. View